Royalty Report: Drugs, Ophthalmological, Pharmaceuticals – Collection: 26243


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Ophthalmological
  • Pharmaceuticals
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26243

License Grant
The Licensor develops prescription pharmaceutical products for ophthalmic and pulmonary diseases.
License Property
The product is Restasis® for dry eye.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 27869

License Grant
A U.S. pharmaceutical announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with another U.S. pharmaceutical company which revises terms related to the Prolacria™ (diquafosol tetrasodium ophthalmic solution) 2% development program and Licensor's right to receive revenues from licensee based on net sales of Restasis® (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Licensee.
License Property
Under the amended agreement, which now runs through December 31, 2020, Licensor is entitled to receive revenues at one global rate based on net sales of Restasis® and any other human ophthalmic formulation of cyclosporine owned or controlled by licensee, with no requirement to co-promote Restasis®. The royalty rate for Restasis® in the United States remains unchanged for 2010. The annual global rate steps down from the 2010 U.S. rate by agreed upon amounts.  

Under the amended agreement, Licensor now has unilateral control over any future Prolacriaâ„¢ development and commercialization. In the event licensee resumes the Prolacriaâ„¢ clinical development program and receives regulatory approval for a Prolacriaâ„¢ product in a particular country, it will have the option to offer Prolacriaâ„¢.

Note that the actual royalty rate is from a press report and this is included at the end of the exhibit.

Field of Use
The drug is to be used for dry eyes.

IPSCIO Record ID: 1449

License Grant
The Company has license agreements with an undisclosed former director wherein the Company has acquired rights to develop and commercialize certain research technologies.

The sale and assignment of Lotemax and Alrex.

License Property
Lotemax and Alrex are the trade names of drug products in the form of eye drop suspensions in which the active compound is loteprednol etabonate ('LE').

Lotemax is a topical, site-specific steroid that is used to treat steroid responsive inflammatory eye conditions. The prescription eye drop is also used for post-operative eye inflammations such as experienced following cataract surgery. The novel chemical structure of Lotemax allows it to be predictably transformed by enzymes in the eye to an inactive metabolite, thereby increasing its safety profile.

Alrex is a specially developed formula of loteprednol etabonate that is used in the treatment of ophthalmic allergies. Alrex is indicated for the treatment of seasonal allergic conjunctivitis, an inflammation of the eye usually caused by pollens. Seasonal allergic conjunctivitis produces itching, tearing, redness and swelling in the conjunctiva, the membrane that covers the inside of the eyelid and the white part of the eye.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.